Big Pharma Pfizer, on the eve of J.P. Morgan, the biggest biopharma dating event on the year, will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.
The move will see it back out of work in Alzheimer’s and Parkinson’s disease, two notoriously difficult areas for the industry, especially the former, which has not seen any real R&D advance in 15 years.
In a statement on Friday, Pfizer said it will be redirecting funds “to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” adding that its total spending on R&D will not change, which amounted to around $8 billion last year.
The ax will fall predominately in Cambridge and Andover, Massachusetts, and in Groton, Connecticut, with about 100 expected at each site.
Those projects up for the chop are preclinical, early and midstage clinical programs primarily focused on Alzheimer’s and Parkinson’s, but Pfizer could outlicense these, or cofund them, through venture investments.
It has a host of meds in these areas, including a phase 2 dopamine 1 activator for Parkinson’s, as well as four phase 1 Alzheimer’s drugs that include PF-05251749 and PF-06648671, a γ-secretase modulator.
This comes after many other Big Pharmas, and smaller biotechs, have failed to move the needle on Alzheimer’s disease drugs in R&D, making ROI on these types of projects precisely zero.
The changes will not hit work on its pain treatments Lyrica and tanezumab, or research into drugs for rare neurological diseases, the Big Pharma stressed.
But the company did say it will set up a neuroscience venture fund “to support continued efforts to advance the field,” although details were not shared. More should come of this later in the year, it adds, and will be focused on external projects.
By Ben Adams
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
